Regeneron Pharmaceuticals reported robust financial results for Q2 2024, with total revenues increasing 12% year-over-year to $3.55 billion. Net income surged 48% to $1.43 billion, or $12.41 per diluted share. The growth was primarily driven by strong sales of EYLEA HD and Dupixent.EYLEA HD, approved in August 2023, generated $304.2 million in U.S. sales for Q2. Combined with EYLEA, total U.S. sales reached $1.53 billion, up 2% YoY. Dupixent global net sales, recorded by Sanofi, rose 27% to $3.56 billion, with Regeneron's share of profits increasing to $988.3 million. Libtayo global net sales grew 42% to $297.4 million.R&D expenses increased 11% to $1.2 billion, reflecting ongoing investments in the pipeline. The company highlighted progress on several clinical programs, including positive results for linvoseltamab in multiple myeloma and DB-OTO in genetic hearing loss. Regeneron maintained a strong balance sheet with $17.5 billion in cash and marketable securities as of June 30, 2024.

Regeneron Pharmaceuticals reported robust financial results for Q2 2024, with total revenues increasing 12% year-over-year to $3.55 billion. Net income surged 48% to $1.43 billion, or $12.41 per diluted share. The growth was primarily driven by strong sales of EYLEA HD and Dupixent.EYLEA HD, approved in August 2023, generated $304.2 million in U.S. sales for Q2. Combined with EYLEA, total U.S. sales reached $1.53 billion, up 2% YoY. Dupixent global net sales, recorded by Sanofi, rose 27% to $3.56 billion, with Regeneron's share of profits increasing to $988.3 million. Libtayo global net sales grew 42% to $297.4 million.R&D expenses increased 11% to $1.2 billion, reflecting ongoing investments in the pipeline. The company highlighted progress on several clinical programs, including positive results for linvoseltamab in multiple myeloma and DB-OTO in genetic hearing loss. Regeneron maintained a strong balance sheet with $17.5 billion in cash and marketable securities as of June 30, 2024.